Clinical Trials on Melanoma Cancer

Total 53784 results

Hoffmann-La Roche

Completed

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

Malignant Melanoma, Cancer

Hungary
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Apexigen America, Inc.

Terminated

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Melanoma | Cancer | Metastatic Melanoma | Melanoma (Skin) | Unresectable Melanoma | Cancer of Skin

Spain, Poland
Grupo Español Multidisciplinar de Melanoma

Recruiting

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain (GEM-1801)

Advanced Cancer | Melanoma Stage Iv | Melanoma Stage Iii

Spain
Assistance Publique Hopitaux De Marseille

Unknown

Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma

Melanoma Cancer

France
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Department of Immunology, The Fourth Hospital of Hebei Medical University

Recruiting

A Clinical Trial of TAA06 Injection in Advanced Solid Tumors

Malignant Melanoma, Lung Cancer, or Colorectal Cancer

China
Delcath Systems Inc.
National Cancer Institute (NCI)

Completed

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Metastatic Cancer | Intraocular Melanoma | Melanoma (Skin)

United States
The Affiliated Hospital of Qingdao University

Recruiting

Real World Study of Four PD-1 Agents in China

Gynecologic Cancer | Thoracic Cancer | Malignant Melanoma | Abdomen Tumors

China
Novo Nordisk A/S

Completed

Efficacy Study of IL-21 to Treat Metastatic Melanoma

Cancer | Malignant Melanoma

Australia
M.D. Anderson Cancer Center
Genta Incorporated

Completed

Phase II Study of Tesetaxel in Metastatic Melanoma

Cancer | Advanced Melanoma

United States
CNAO National Center of Oncological Hadrontherapy

Recruiting

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract (CYCLE)

Gynecologic Cancer | Malignant Melanoma

Italy
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
Gustav Stalhammar
The Swedish Society of Medicine; Swedish Cancer Society; Karolinska Trial Alliance and other collaborators

Recruiting

Adjuvant Melatonin for Uveal Melanoma (AMUM)

Uveal Melanoma | Uveal Melanoma, Posterior, Medium/Large Size | Eye Cancer, Intraocular Melanoma

Sweden
Pfizer

Completed

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Melanoma and Metastatic Colorectal Cancer

United States, Spain, France, Japan, Australia, Switzerland, Norway
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
Replimune Inc.

Recruiting

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Cancer | NSCLC | Melanoma (Skin) | Microsatellite Instability | Cutaneous Melanoma | Mismatch Repair Deficiency | Non-melanoma Skin Cancer

United States, Spain, France, United Kingdom, Germany
National Cancer Institute (NCI)

Completed

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental | Experimental Melanomas

United States
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Cancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
University of Oklahoma

Completed

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

Metastatic Cancer | Melanoma (Skin)

United States
European Organisation for Research and Treatment...

Terminated

Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain

Metastatic Cancer | Melanoma (Skin)

France, Norway, Belgium, Netherlands, United Kingdom, Austria, Czech Republic, Germany, Italy, Portugal, Switzerland
MelanomaPRO, Russia

Recruiting

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (ISABELLA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, Ocular

Russian Federation
National Cancer Institute (NCI)

Recruiting

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Mucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditions

United States, Canada
University of Utah

Completed

Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma

Cancer

United States
Northwestern University

Completed

Promoting Early Detection of Melanoma During the Mammography Experience

Melanoma (Skin Cancer)

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Metastatic Cancer | Melanoma (Skin)

United States
Maxim Pharmaceuticals
National Cancer Institute (NCI)

Unknown

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Metastatic Cancer | Melanoma (Skin)

United States, Canada, Germany, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Iovance Biotherapeutics, Inc.; Prometheus Inc.

Completed

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Skin Cancer | Melanoma (Skin)

United States
Sunnybrook Health Sciences Centre
Terry Fox Research Institute

Recruiting

MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer

Melanoma

Canada
Viewpoint Molecular Targeting
Mayo Clinic

Completed

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR1)

Melanoma (Skin) | Melanoma Stage IV | Melanoma, Uveal | Melanoma, Mucosal

United States
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus
Delcath Systems Inc.

Active, not recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Institut Curie
Genentech, Inc.

Completed

A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)

Breast Cancer | Cutaneous Melanoma

France
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Skin Cancer | Metastatic Melanoma

United States
University of Massachusetts, Worcester
National Cancer Institute (NCI)

Completed

Investigation of a Behavioral Substitute for Sunbathing

Skin Cancer | Melanoma (Skin)

United States
Dana-Farber Cancer Institute
World Cancer Research Fund International

Not yet recruiting

Exercise and Diet Interventions During Immunotherapy in Melanoma Patients

Skin Cancer | Melanoma (Skin) | Advanced Melanoma

United States
University of Pennsylvania

Terminated

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

Breast Cancer | Malignant Melanoma

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Institut National de la Santé Et de la Recherche Médicale, France; Martin-Luther-Universität... and other collaborators

Unknown

Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial (DIgesT)

Breast Cancer | Melanoma, Malignant

Italy
Brian Køster

Completed

Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations

Skin Cancer | Malignant Melanoma | Non-melanoma Skin Cancer | Sunburn | Ultraviolet Radiation Exposure | Keratinocyte Skin Cancer

Denmark
Scancell Ltd

Recruiting

SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

Melanoma (Skin) | Malignant Melanoma | Melanoma Stage IV | Melanoma Stage III

United Kingdom
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Institut Curie

Active, not recruiting

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Triple Negative Breast Cancer | Pediatric Cancer | Metastatic Uveal Melanoma | Luminal B Breast Cancer

France
Regeneron Pharmaceuticals
Bristol-Myers Squibb

Completed

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Melanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
Regeneron Pharmaceuticals
Bristol-Myers Squibb

Active, not recruiting

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Melanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
Dana-Farber Cancer Institute
Partner Therapeutics (PTx)

Withdrawn

Sargramostim (GM-CSF) + PD-1

Metastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center; NYU Langone Health

Completed

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Skin Cancer | Metastatic Melanoma | Neoplasm

United States
Hoffmann-La Roche

Completed

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma

Spain, United States, Belgium, Denmark, Canada, Australia
University of California, Irvine
Pfizer

Completed

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Melanoma | Malignant Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States

Clinical Trials on Melanoma Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations